LFVNearnings
- Next report
- No date yet
- none in the next 8 weeks
- Last result
- $0.05Beat
- vs $0.03 expected on Nov 9
- Price
- $5.11
- +8.26% today · $80.4M cap
Past and upcoming reports
1
| Nov 9, 2026 | Sep 30, 2026 | After the market closes | $0.03 | Beat$0.05 |
After the report
Nov 9, 2026 report
LFVN beat EPS estimates, but weak growth and a persistent technical downtrend kept the setup mixed
LifeVantage reported $0.05 EPS for the quarter ended September 30, beating the $0.03 estimate by 66.7%. Shares rose 4.82% to $4.78 on November 11, but remained below the 20-day, 50-day, and 200-day moving averages. No company-specific post-earnings news or explicit guidance was provided.
Reported against expected
BeatReported EPS was $0.05 versus a $0.03 estimate, a $0.02 or 66.7% beat, reported November 9, 2026.
Guidance
No explicit management guidance was provided in the payload. forward EPS growth was estimated at 19.59%.
How the stock reacted
Shares rose $0.22, or 4.82%, to $4.78 on November 11, with 57,332 shares traded. event-day reaction data was unavailable.
What changed
EPS reached $0.05, $0.02 above estimates, while forward EPS growth was projected at 19.59%.
What the price now assumes
The 4.82% rebound contrasts with a 20.67% monthly decline and price below all three major moving averages.
What it means for the business
Maintain a neutral-to-cautious bias. upgrade only if price reclaims $5.56 and forward EPS growth remains 19.59%.
The next one to three months, as we saw it then
Better case30%
The EPS beat develops into a broader recovery if projected 19.59% next-year EPS growth supports renewed buying.
Base case40%
The stock stabilizes after the beat but remains range-bound while valuation support competes with weak operating momentum.
Worse case30%
The EPS beat proves insufficient as negative TTM revenue growth, a 3.67% operating margin, and weak momentum dominate.
If you hold it
Hold unless next-quarter revenue misses guidance materially or customer concentration risk worsens.
If you are watching
Add only if next-quarter guidance is reiterated or raised. avoid if guidance is cut or geopolitical risk escalates.
Scenario odds are a judgement, not measured.